论文部分内容阅读
AIM To assess the incidence of hepatitis B virus(HBV)reactivation in patients receiving direct-acting antiviral agent(DAA)-based therapy or interferon(IFN)-based therapy for hepatitis C and the effectiveness of preemptive anti-HBV therapy for preventing H